ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ACAD Acadia Pharmaceuticals Inc

17.05
-0.03 (-0.18%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Acadia Pharmaceuticals Inc NASDAQ:ACAD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.03 -0.18% 17.05 16.90 31.00 17.5839 17.03 17.44 1,160,279 05:00:00

ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020

24/02/2020 2:00pm

Business Wire


Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Acadia Pharmaceuticals Charts.

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it will present at the Cowen and Company 40th Annual Health Care Conference in Boston on Monday, March 2, 2020, at 2:10 p.m. Eastern Time.

A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through April 2, 2020.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, major depressive disorder, the negative symptoms of schizophrenia, and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

Media Contact: ACADIA Pharmaceuticals Inc. Stephanie Fagan (858) 212-0534 media@acadia-pharm.com

Investor Contact: ACADIA Pharmaceuticals Inc. Mark Johnson, CFA (858) 261-2771 ir@acadia-pharm.com

1 Year Acadia Pharmaceuticals Chart

1 Year Acadia Pharmaceuticals Chart

1 Month Acadia Pharmaceuticals Chart

1 Month Acadia Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock